Key facts
- Anto Biosciences’s last known valuation is $30.0M (Jan 2026).
- It has raised $600K; the latest was Early Stage VC ($100K) in Jan 2026.
- Notable investors include Y Combinator, RRE Ventures, Ritual Capital, Massive Tech Ventures, Standard Partners — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Anto Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Anto Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anto Biosciences
Developer of a multimodal foundation model designed to make the gut microbiome computable and improve understanding of drug response. The company offers a platform that models microbial communities and predicts drug toxicity and efficacy across diverse populations, enabling pharmaceutical researchers to design and optimize molecules for broader effectiveness and reduced failure rates.
- Sector
- Business Products and Services (B2B)
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 2
- Website
- anto.bio/
- Ownership
- Privately Held (backing)
Anto Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anto Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anto Biosciences in its N-PORT filings yet. We sweep new filings monthly.